Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CRON 
Cronos Group Inc (CRON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: CRON (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -34.08% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 736.15M USD | Price to earnings Ratio 13.64 | 1Y Target Price 1.94 |
Price to earnings Ratio 13.64 | 1Y Target Price 1.94 | ||
Volume (30-day avg) 1934319 | Beta 1.52 | 52 Weeks Range 1.60 - 2.54 | Updated Date 06/18/2025 |
52 Weeks Range 1.60 - 2.54 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 39.69% | Operating Margin (TTM) -10.9% |
Management Effectiveness
Return on Assets (TTM) -2.42% | Return on Equity (TTM) 4.59% |
Valuation
Trailing PE 13.64 | Forward PE - | Enterprise Value -100751773 | Price to Sales(TTM) 5.91 |
Enterprise Value -100751773 | Price to Sales(TTM) 5.91 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA -1.42 | Shares Outstanding 385419008 | Shares Floating 204815522 |
Shares Outstanding 385419008 | Shares Floating 204815522 | ||
Percent Insiders 46.73 | Percent Institutions 14.32 |
Analyst Ratings
Rating 3.4 | Target Price 1.94 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 2 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cronos Group Inc
Company Overview
History and Background
Cronos Group Inc. was founded in 2012, initially as PharmaCan Capital. It evolved into a globally diversified cannabis company with production and distribution across multiple continents. Significant milestones include becoming the first cannabis company to list on the Nasdaq and securing a major investment from Altria Group.
Core Business Areas
- Hemp-Derived CBD: Focuses on producing and marketing hemp-derived CBD products, including tinctures, topicals, and edibles.
- Cultivation and Production: Cultivates and produces cannabis and cannabis-derived products for recreational and medical markets.
- Research and Development: Invests in research and development to create innovative cannabis products and technologies.
Leadership and Structure
The leadership team comprises experienced professionals in the cannabis and consumer packaged goods industries. The organizational structure includes departments for cultivation, production, sales, marketing, and research and development.
Top Products and Market Share
Key Offerings
- Peace Naturals: A brand of medical cannabis products. Market share information is difficult to pinpoint specifically, but Cronos operates in a highly competitive market with companies such as Tilray (TLRY) and Canopy Growth (CGC).
- Spinach: A brand focused on the recreational cannabis market, known for its variety of strains. Exact market share data is difficult to ascertain. Competitors include Aurora Cannabis (ACB) and Organigram (OGI).
- Lord Jones: A premium hemp-derived CBD brand. The CBD market is highly fragmented and competitive. Competitors include Charlotte's Web (CWBHF).
Market Dynamics
Industry Overview
The cannabis industry is experiencing growth and regulatory changes as more jurisdictions legalize cannabis for medical and recreational use. This includes the growth of CBD from hemp and the rise of cannabis-infused products.
Positioning
Cronos Group is positioned as a global cannabis company focused on premium brands and innovative product development. Its investment from Altria provides it with financial resources and expertise in regulated industries.
Total Addressable Market (TAM)
Estimates suggest the global cannabis market could reach hundreds of billions of dollars in the coming years. Cronos is attempting to capture a portion of this TAM by focusing on high-quality products and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong partnership with Altria Group (MO)
- Global presence and distribution network
- Focus on research and development
- Diverse product portfolio
- Strong brand recognition in certain markets
Weaknesses
- Limited profitability and history of losses
- High operating expenses
- Dependence on regulatory changes
- Relatively small market share compared to leading competitors
- Concentrated in a few key markets
Opportunities
- Expansion into new legal cannabis markets
- Development of innovative cannabis products
- Further penetration of existing markets
- Strategic acquisitions and partnerships
- Increase in global legalization
Threats
- Intense competition in the cannabis industry
- Regulatory uncertainty and changes
- Fluctuations in cannabis prices
- Potential for oversupply in the market
- Negative public perception of cannabis
Competitors and Market Share
Key Competitors
- TLRY
- CGC
- ACB
- OGI
Competitive Landscape
Cronos Group has a strategic advantage due to its partnership with Altria. However, competitors such as Tilray and Canopy Growth have greater market share and brand recognition in some markets.
Major Acquisitions
Lord Jones
- Year: 2019
- Acquisition Price (USD millions): 300
- Strategic Rationale: To expand into the hemp-derived CBD market and leverage the brand's reputation for premium products.
Growth Trajectory and Initiatives
Historical Growth: Cronos Group has experienced revenue growth, driven by expanding cannabis markets and product innovation. However, growth has been uneven, and the company has not consistently achieved profitability.
Future Projections: Analyst estimates vary widely, reflecting the uncertainty of the cannabis industry. Future growth is expected to be driven by new markets and product categories.
Recent Initiatives: Recent initiatives include expanding production capacity, launching new products, and pursuing strategic partnerships.
Summary
Cronos Group benefits from a strategic partnership with Altria, providing financial strength and industry expertise, while operating in a high growth industry. However, they struggle with profits and face intense competition from companies with higher market share. Cronos needs to manage regulatory changes carefully as they continue to expand production capacity and launch new products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Analyst Reports, Market Research Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cronos Group Inc
Exchange NASDAQ | Headquaters Stayner, ON, Canada | ||
IPO Launch date 2016-07-12 | President, CEO & Chairman Mr. Michael Ryan Gorenstein J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 459 | Website https://thecronosgroup.com |
Full time employees 459 | Website https://thecronosgroup.com | ||
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brand names. The company is based in Stayner, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.